These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 15199342)

  • 1. Can change in high-density lipoprotein cholesterol levels reduce cardiovascular risk?
    Dean BB; Borenstein JE; Henning JM; Knight K; Merz CN
    Am Heart J; 2004 Jun; 147(6):966-76. PubMed ID: 15199342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.
    Evans M; Roberts A; Davies S; Rees A
    Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
    Hausenloy DJ; Yellon DM
    Heart; 2008 Jun; 94(6):706-14. PubMed ID: 18480348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of non-HDL cholesterol in risk stratification for coronary artery disease.
    Rana JS; Boekholdt SM; Kastelein JJ; Shah PK
    Curr Atheroscler Rep; 2012 Apr; 14(2):130-4. PubMed ID: 22203405
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HDL-C: role as a risk modifier.
    Barter P
    Atheroscler Suppl; 2011 Nov; 12(3):267-70. PubMed ID: 22152280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-density lipoprotein cholesterol as a therapeutic target to reduce cardiovascular events.
    Fonarow GC; Watson KE
    Am Heart J; 2004 Jun; 147(6):939-41. PubMed ID: 15199335
    [No Abstract]   [Full Text] [Related]  

  • 8. Emerging strategies and agents to lower cardiovascular risk by increasing high density lipoprotein cholesterol levels.
    Greenfeder S
    Curr Med Chem; 2009; 16(2):144-56. PubMed ID: 19149567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipoprotein(a), cardiovascular disease, and contemporary management.
    Jacobson TA
    Mayo Clin Proc; 2013 Nov; 88(11):1294-311. PubMed ID: 24182706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
    Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis.
    Nicholls SJ; Tuzcu EM; Sipahi I; Grasso AW; Schoenhagen P; Hu T; Wolski K; Crowe T; Desai MY; Hazen SL; Kapadia SR; Nissen SE
    JAMA; 2007 Feb; 297(5):499-508. PubMed ID: 17284700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HDL-C levels and revascularization procedures in coronary heart disease patients treated with statins to target LDL-C levels.
    Elis A; Pereg D; Froom P; Lishner M; Segev D; Hermoni D
    Clin Cardiol; 2011 Sep; 34(9):572-6. PubMed ID: 21887688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The beneficial effects of raising high-density lipoprotein cholesterol depends upon achieved levels of low-density lipoprotein cholesterol during statin therapy: Implications for coronary atheroma progression and cardiovascular events.
    Puri R; Nissen SE; Shao M; Kataoka Y; Uno K; Kapadia SR; Tuzcu EM; Nicholls SJ
    Eur J Prev Cardiol; 2016 Mar; 23(5):474-85. PubMed ID: 25691546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The relative role of low-density lipoprotein cholesterol and high-density lipoprotein cholesterol in coronary artery disease: evidence from large-scale statin and fibrate trials.
    Sacks FM
    Am J Cardiol; 2001 Dec; 88(12A):14N-18N. PubMed ID: 11788125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.
    Reiner Z
    Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):799-807. PubMed ID: 23932901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial.
    Stender S; Schuster H; Barter P; Watkins C; Kallend D;
    Diabetes Obes Metab; 2005 Jul; 7(4):430-8. PubMed ID: 15955130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pitavastatin: novel effects on lipid parameters.
    Chapman MJ
    Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Projected coronary heart disease risk benefit with ezetimibe.
    Davies GM; Cook JR; Erbey J; Alemao E; Veltri EP
    Atherosclerosis; 2005 Apr; 179(2):375-8. PubMed ID: 15777556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HDL hypothesis: where do we stand now?
    Tariq SM; Sidhu MS; Toth PP; Boden WE
    Curr Atheroscler Rep; 2014 Apr; 16(4):398. PubMed ID: 24619460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HMG-CoA reductase inhibitor (Statin) therapy and coronary atherosclerosis in Japanese subjects: role of high-density lipoprotein cholesterol.
    Tani S; Nagao K; Hirayama A
    Am J Cardiovasc Drugs; 2011 Dec; 11(6):411-7. PubMed ID: 22149320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.